Loading patent…
AssigneeSugen, Inc.
InventorsKlaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers, Fairooz F. Kabbinavar, Dennis Slamon, Peng Cho Tang
Estimating the term…
The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
A method of treating a patient suffering from a blood vessel proliferative disorder characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a therapeutically effective amount of a compound selected from the group consisting of 5-methyl-isoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide, and pharmaceutically acceptable salts thereof,
A method of treating a patient suffering from a blood vessel proliferative disorder characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of 5-methyl-isoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide, and pharmaceutically acceptable salts thereof,
Dependencies are inferred from the claim text.